pharma · Lymphoma of B-cell origin · Malignant Solid Tumors
Genmab
Genmab A/S
Genmab clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Carl Jacobsens Vej 30, 2500 Valby, DK
- Employees
- 2,847
- Programs
- 29
- Drugs
- 56
- Patents
- 0
Genmab projects
6 ClinicalTrials.gov programs sponsored by Genmab.
Genmab has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A Study of GEN1106 in Participants with Solid Tumors
Genmab A/S
Metastatic or advanced malignant solid tumors
1 trial -
GCT1056-01
Genmab A/S
Advanced solid tumors
1 trial -
GCT1057-01
Genmab A/S
Metastatic or advanced malignant solid tumors
1 trial -
GCT1079-01
Genmab A/S
Advanced Malignant Solid Tumors
1 trial -
GCT3018-01
Genmab A/S
Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
1 trial -
GEN1042
Genmab A/S
Malignant Solid Tumor
1 trial
Frequently asked questions
How many clinical projects does Genmab have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.